Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ensysce Biosciences Inc ENSCW


Primary Symbol: ENSC

Healthcare Biotechnology
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Recent & Breaking News (NDAQ:ENSC)

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Accesswire 11 days ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Accesswire November 7, 2024

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Accesswire October 8, 2024

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Accesswire October 2, 2024

Ensysce Biosciences Receives Notice from Nasdaq

Accesswire September 27, 2024

Ensysce Biosciences Presenting at Upcoming Meetings

Accesswire September 24, 2024

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Accesswire September 19, 2024

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Accesswire September 13, 2024

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Accesswire August 29, 2024

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Accesswire August 27, 2024

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Accesswire August 27, 2024

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Accesswire August 14, 2024

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Accesswire August 7, 2024

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Accesswire July 9, 2024

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

Accesswire June 27, 2024

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

Accesswire June 25, 2024

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

Accesswire June 6, 2024

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

Accesswire June 3, 2024

Ensysce Biosciences Regains Compliance with Nasdaq

Accesswire May 28, 2024

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

Accesswire May 20, 2024